Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Expert Opinion / Cases · August 23, 2023

Metastatic HR+/HER2− Breast Cancer With Co-Existing ESR1 and PIK3CA Mutation

Written by
Naomi G. Dempsey MD

 

Discuss This item Follow

No comments yet, be the first to start the discussion!

  • nguyen nguyen

    Aug 24, 2023

    Choose between these two combinations
    Denosumab, Everolimus, Fulvestrant, T-DxD
    Denosumab, Everolimus, Fulvestrant, Apelisib
    

  • Comment deleted by Moderator.
  • FAZEL ELAHI

    Aug 25, 2023

    fulvestrant +alpelisib

  • Susan Sadighi

    Aug 25, 2023

    Denosumab, Fulvestrant, Apelisib

  • Milka Gonzalez

    Aug 25, 2023

    I choose Alpelisib + Fulvestrant +/- Elacestrant and Denosumab

  • nagib khoury

    Aug 26, 2023

    fulvestrtant , apelisib, denosumab,thus targeting both mutations in esr1 andpi3k and bone health

  • Silvia Falcon

    Aug 28, 2023

    Alpelisib + Fulvestrant + Denosumab

  • pramod kumar julka

    Aug 28, 2023

    Alpelisib fulvestrant denosumab 

  • FAZEL ELAHI

    Sep 09, 2023

    thanks

  • Mar 02, 2024

    Pending Moderator approval.
    Delete

Further Reading